Showing results (1591-1600 of 12,170) with videos related to
Sort By:
Pageof 1,217
Journal of Cardiovascular Pharmacology|September 10, 1998
Beta-blockers for chronic heart failure: from prejudice to enlightenmentJ G Cleland, J McGowan, P J CowburnJournal of Cardiovascular Pharmacology|January 13, 2004
Disruption of the actin cytoskeleton up-regulates iNOS expression in vascular smooth muscle cellsYoshiyuki Hattori, Kikuo KasaiJournal of Cardiovascular Pharmacology|January 13, 2004
Endothelial and smooth muscle cell dysfunction in human atherosclerotic radial artery: implications for coronary artery bypass graftingBarbara E Stähli, Rosmarie F Caduff, Helen Greutert, et al.Journal of Cardiovascular Pharmacology|January 13, 2004
Nitric oxide and prostaglandins modulate pressure-induced myogenic responses of intramural coronary arteriolesMaria Szekeres, György L Nádasy, Gabor Kaley, et al.Journal of Cardiovascular Pharmacology|January 13, 2004
Cardiovascular effects of eugenol, a phenolic compound present in many plant essential oils, in normotensive ratsSaad Lahlou, Leylliane Fátima Leal Interaminense, Pedro Jorge Caldas Magalhães, et al.Journal of Cardiovascular Pharmacology|January 13, 2004
Enalapril interferes with the effect of diclofenac on leucocyte-endothelium interaction in hypertensive ratsLuis Lopez Martinez, Maria Aparecida Oliveira, Ana Silvia Miguel, et al.Journal of Cardiovascular Pharmacology|April 13, 2004
Role of histamine H3 receptors during ischemia/reperfusion in isolated rat heartsSatoshi Yamamoto, Isao Tamai, Masanori Takaoka, et al.Journal of Cardiovascular Pharmacology|April 9, 2004
Carvedilol inhibits basal and stimulated ACE production in human endothelial cellsOuti Saijonmaa, Tuulikki Nyman, Frej FyhrquistJournal of Cardiovascular Pharmacology|April 9, 2004
The isoflavone metabolite cis-tetrahydrodaidzein inhibits ERK-1 activation and proliferation in human vascular smooth muscle cellsShanhong Ling, Aozhi Dai, Maro R I Williams, et al.Journal of Cardiovascular Pharmacology|April 9, 2004
Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefitsVictor L Serebruany, Alex I Malinin, David R Lowry, et al.Pageof 1,217